Should medication be refused on the NHS?

 Scrotnig 

A drug that can prolong the lives of patients with advanced liver cancer has been rejected for use in the NHS in England, Wales and Northern Ireland. Is this the right decision?

The National Institute for Health and Clinical Excellence (NICE) said the cost of Nexavar, also rejected in Scotland, was "simply too high" at about £3,000 a month. But Macmillan Cancer Support called the decision "a scandal".

More than 3,000 people are diagnosed with liver cancer every year in the UK and their prognosis is generally poor. Only about 20% of patients are alive one year after diagnosis, dropping to just 5% after five years.

Should medication be refused on the NHS? That's Today's Big Question.